Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation

Björn Gustafsson, Susan Youens, Angelique Y. Louie

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Atherosclerosis is a leading cause of death in the U.S. Because there is a potential to prevent coronary and arterial disease through early diagnosis, there is a need for methods to image arteries in the subclinical stage as well as clinical stage using various noninvasive techniques, including magnetic resonance imaging (MRI). We describe a development of a novel MRI contrast agent targeted to plaques that will allow imaging of lesion formation. The contrast agent is directed to macrophages, one of the earliest components of developing plaques. Macrophages are labeled through the macrophage scavenger receptor A, a macrophage specific cell surface protein, using an MRI contrast agent derived from scavenger receptor ligands. We have synthesized and characterized these contrast agents with a range of relaxivities. In vitro studies show that the targeted contrast agent accumulates in macrophages, and solution studies indicate that micromolar concentrations are sufficient to produce contrast in an MR image. Cell toxicity and initial biodistribution studies indicate low toxicity, no detectable retention in normal blood vessels, and rapid clearance from blood. The promising performance of this contrast agent targeted toward vascular inflammation opens doors to tracking of other inflammatory diseases such as tumor immunotherapy and transplant acceptance using MRI.

Original languageEnglish (US)
Pages (from-to)538-547
Number of pages10
JournalBioconjugate Chemistry
Volume17
Issue number2
DOIs
StatePublished - Mar 2006

Fingerprint

Scavenger Receptors
Macrophages
Magnetic resonance
Contrast Media
Blood Vessels
Magnetic Resonance Imaging
Inflammation
Imaging techniques
Toxicity
Transplants
Blood vessels
Immunotherapy
Coronary Disease
Tumors
Early Diagnosis
Cause of Death
Atherosclerosis
Membrane Proteins
Blood
Arteries

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Clinical Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry

Cite this

Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation. / Gustafsson, Björn; Youens, Susan; Louie, Angelique Y.

In: Bioconjugate Chemistry, Vol. 17, No. 2, 03.2006, p. 538-547.

Research output: Contribution to journalArticle

Gustafsson, Björn ; Youens, Susan ; Louie, Angelique Y. / Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation. In: Bioconjugate Chemistry. 2006 ; Vol. 17, No. 2. pp. 538-547.
@article{9b9366cf30f24643b2eb5f9635dbfdf7,
title = "Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation",
abstract = "Atherosclerosis is a leading cause of death in the U.S. Because there is a potential to prevent coronary and arterial disease through early diagnosis, there is a need for methods to image arteries in the subclinical stage as well as clinical stage using various noninvasive techniques, including magnetic resonance imaging (MRI). We describe a development of a novel MRI contrast agent targeted to plaques that will allow imaging of lesion formation. The contrast agent is directed to macrophages, one of the earliest components of developing plaques. Macrophages are labeled through the macrophage scavenger receptor A, a macrophage specific cell surface protein, using an MRI contrast agent derived from scavenger receptor ligands. We have synthesized and characterized these contrast agents with a range of relaxivities. In vitro studies show that the targeted contrast agent accumulates in macrophages, and solution studies indicate that micromolar concentrations are sufficient to produce contrast in an MR image. Cell toxicity and initial biodistribution studies indicate low toxicity, no detectable retention in normal blood vessels, and rapid clearance from blood. The promising performance of this contrast agent targeted toward vascular inflammation opens doors to tracking of other inflammatory diseases such as tumor immunotherapy and transplant acceptance using MRI.",
author = "Bj{\"o}rn Gustafsson and Susan Youens and Louie, {Angelique Y.}",
year = "2006",
month = "3",
doi = "10.1021/bc060018k",
language = "English (US)",
volume = "17",
pages = "538--547",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation

AU - Gustafsson, Björn

AU - Youens, Susan

AU - Louie, Angelique Y.

PY - 2006/3

Y1 - 2006/3

N2 - Atherosclerosis is a leading cause of death in the U.S. Because there is a potential to prevent coronary and arterial disease through early diagnosis, there is a need for methods to image arteries in the subclinical stage as well as clinical stage using various noninvasive techniques, including magnetic resonance imaging (MRI). We describe a development of a novel MRI contrast agent targeted to plaques that will allow imaging of lesion formation. The contrast agent is directed to macrophages, one of the earliest components of developing plaques. Macrophages are labeled through the macrophage scavenger receptor A, a macrophage specific cell surface protein, using an MRI contrast agent derived from scavenger receptor ligands. We have synthesized and characterized these contrast agents with a range of relaxivities. In vitro studies show that the targeted contrast agent accumulates in macrophages, and solution studies indicate that micromolar concentrations are sufficient to produce contrast in an MR image. Cell toxicity and initial biodistribution studies indicate low toxicity, no detectable retention in normal blood vessels, and rapid clearance from blood. The promising performance of this contrast agent targeted toward vascular inflammation opens doors to tracking of other inflammatory diseases such as tumor immunotherapy and transplant acceptance using MRI.

AB - Atherosclerosis is a leading cause of death in the U.S. Because there is a potential to prevent coronary and arterial disease through early diagnosis, there is a need for methods to image arteries in the subclinical stage as well as clinical stage using various noninvasive techniques, including magnetic resonance imaging (MRI). We describe a development of a novel MRI contrast agent targeted to plaques that will allow imaging of lesion formation. The contrast agent is directed to macrophages, one of the earliest components of developing plaques. Macrophages are labeled through the macrophage scavenger receptor A, a macrophage specific cell surface protein, using an MRI contrast agent derived from scavenger receptor ligands. We have synthesized and characterized these contrast agents with a range of relaxivities. In vitro studies show that the targeted contrast agent accumulates in macrophages, and solution studies indicate that micromolar concentrations are sufficient to produce contrast in an MR image. Cell toxicity and initial biodistribution studies indicate low toxicity, no detectable retention in normal blood vessels, and rapid clearance from blood. The promising performance of this contrast agent targeted toward vascular inflammation opens doors to tracking of other inflammatory diseases such as tumor immunotherapy and transplant acceptance using MRI.

UR - http://www.scopus.com/inward/record.url?scp=33645464505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645464505&partnerID=8YFLogxK

U2 - 10.1021/bc060018k

DO - 10.1021/bc060018k

M3 - Article

C2 - 16536488

AN - SCOPUS:33645464505

VL - 17

SP - 538

EP - 547

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 2

ER -